"Alemtuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
| Descriptor ID |
D000074323
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.313 D12.776.124.790.651.114.224.060.375 D12.776.377.715.548.114.224.200.375
|
| Concept/Terms |
Campath 1H- Campath 1H
- Monoclonal Antibody Campath-1H
- Antibody Campath-1H, Monoclonal
- Campath-1H, Monoclonal Antibody
- Monoclonal Antibody Campath 1H
- Campath-1H
- Campath1H
Campath 1G- Campath 1G
- Campath-1-G
- Campath 1 G
- Campath1G
- Campath-1G
|
Below are MeSH descriptors whose meaning is more general than "Alemtuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Alemtuzumab [D12.776.124.486.485.114.224.060.313]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Alemtuzumab [D12.776.124.790.651.114.224.060.375]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Below are MeSH descriptors whose meaning is more specific than "Alemtuzumab".
This graph shows the total number of publications written about "Alemtuzumab" by people in this website by year, and whether "Alemtuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 4 | 8 | 12 |
| 2018 | 7 | 2 | 9 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Alemtuzumab" by people in Profiles.
-
SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature. Neurol Sci. 2021 Dec; 42(12):4881-4884.
-
Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis. Neurol Sci. 2021 10; 42(10):4003-4005.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Alemtuzumab in Covid era. Mult Scler Relat Disord. 2021 Jun; 51:102908.
-
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clin Neurol Neurosurg. 2020 10; 197:106203.
-
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID. Mult Scler Relat Disord. 2020 Nov; 46:102447.
-
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab. Mult Scler Relat Disord. 2020 Oct; 45:102402.
-
Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020 Jul; 41(7):1647-1650.
-
COVID-19 will change MS care forever - No. Mult Scler. 2020 09; 26(10):1149-1151.
-
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab. Mult Scler Relat Disord. 2020 09; 44:102314.